强化血压控制与标准血压控制的心血管及肾脏结局获益-危害权衡:随机对照试验的个体参与者数据分析
该研究为六项随机对照试验(ACCORD BP、SPRINT、ESPRIT、BPROAD、STEP、CRHCP)的事后汇总个体参与者数据分析,纳入80220例参与者,强化组40503例、标准组39717例。中位随访3.2年,强化血压控制组主要心血管复合终点发生率为5.3%,标准组为7.1%(HR 0.76,95%CrI 0.72-0.81;p<0.0001)。强化组心血管疾病绝对风险降低1.73%(NNT 58),不良事件绝对风险增加1.82%(NNH 55),总体净获益为1.14(95%CrI 1.03-1.25),考虑肾脏相关不良事件时净获益仍为正(1.13)。作者认为强化血压控制在心脑血管事件减少与不良事件增加之间提供净获益。
要点
- 强化血压控制(收缩压目标<120或<130 mm Hg)较标准治疗降低主要心血管复合终点(心梗、卒中、心衰、心血管死亡):5.3% vs 7.1%,HR 0.76(95%CrI 0.72-0.81)。
- 强化组心血管疾病绝对风险降低1.73%(95%CrI 1.65-1.81),NNT 58(95%CrI 55-61)。
- 强化组不良事件(如低血压、晕厥)绝对风险增加1.82%(95%CrI 1.63-2.01),NNH 55(95%CrI 49-61)。
- 总体净获益为1.14(95%CrI 1.03-1.25);考虑肾脏相关不良事件时净获益仍为正(1.13,95%CrI 1.01-1.24)。
- 中位随访3.2年,强化血压控制组与标准组主要心血管复合终点发生率分别为5.3%与7.1%。
适用人群与场景
- 六项随机对照试验(ACCORD BP、SPRINT、ESPRIT、BPROAD、STEP、CRHCP)的参与者,共80220例,强化组40503例、标准组39717例。
- 中位年龄64.0岁(IQR 59.0-70.0),男性39043例(48.7%),女性41177例(51.3%),亚洲人66290例(82.6%),白人8097例(10.1%)。
诊断标准与关键阈值
- 强化血压控制定义为收缩压目标<120 mm Hg或<130 mm Hg。
- 标准治疗定义为收缩压目标<140 mm Hg、老年人<150 mm Hg或常规治疗,取决于试验设计。
研究设计与关键结果
- 研究类型:六项随机对照试验的事后汇总个体参与者数据分析,纳入80220例参与者(强化组40503例,标准组39717例)。
- 主要获益终点为主要心血管复合终点(心肌梗死、卒中、心力衰竭、心血管死亡):强化组2158例(5.3%)vs 标准组2811例(7.1%),HR 0.76(95%CrI 0.72-0.81;p<0.0001)。
- 强化组心血管疾病绝对风险降低1.73%(95%CrI 1.65-1.81),NNT 58(95%CrI 55-61)。
- 主要危害终点为不良事件(如低血压、晕厥):强化组绝对风险增加1.82%(95%CrI 1.63-2.01),NNH 55(95%CrI 49-61)。
- 总体净获益为1.14(95%CrI 1.03-1.25,采用裁定加权);考虑肾脏相关不良事件时净获益为1.13(95%CrI 1.01-1.24)。
证据类型、等级与局限
- 证据类型:六项随机对照试验的个体参与者数据汇总分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与标准血压控制相比,强化血压控制在心脑血管事件减少与不良事件(包括肾脏事件)增加之间提供净获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although intensive blood pressure control is recommended by major guidelines, its overall benefit-harm balance remains uncertain. In particular, it is unclear how net clinical benefit varies by blood pressure target and patient characteristics. We aimed to quantify the benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control.
METHODS: We conducted a post-hoc, pooled participant-level analysis of six randomised controlled trials (ACCORD BP, SPRINT, ESPRIT, BPROAD, STEP, and CRHCP). Trial selection was based on our collaborative framework, the Blood Pressure Reduction Union-Landmark Evidence, and a targeted literature search, guided by five predefined inclusion criteria: (1) comparison of intensive systolic blood pressure targets (<120 mm Hg or <130 mm Hg) versus standard treatment; (2) reporting of composite major cardiovascular outcomes; (3) enrolment of more than 2000 participants; (4) standardised reporting of treatment-related adverse events; and (5) availability of individual participant data. We also conducted a systematic review in which we searched PubMed for studies published from database inception up to June 15, 2025, with no language restrictions. We used search terms related to cardiovascular outcomes, hypertension, intensive blood pressure lowering, and randomised trials. Study screening and data extraction were independently conducted in pairs by ten reviewers, with discrepancies resolved by discussion or adjudication. Participants in the six trials were randomly assigned to intensive blood pressure treatment (systolic blood pressure target <120 mm Hg or <130 mm Hg) versus standard treatment (systolic blood pressure target <140 mm Hg, <150 mm Hg in older adults, or usual care), depending on the trial design. The primary benefit outcome was a composite of myocardial infarction, stroke, heart failure, and cardiovascular death. The primary harm outcomes were adverse events of interest (eg, hypotension and syncope) and renal-related events. Statistical analyses were performed on an intention-to-treat basis using Bayesian hierarchical models.
FINDINGS: The initial dataset included 80 676 participants, of whom 80 220 were included in our analyses (intensive blood pressure control group n=40 503; standard blood pressure control group n=39 717). The median age was 64·0 years (IQR 59·0-70·0), 39 043 (48·7%) participants were male, and 41 177 (51·3%) were female. Most participants were Asian (66 290 [82·6%]) or White (8097 [10·1%]). During a median follow-up of 3·2 years (IQR 3·0-3·5), the composite cardiovascular disease outcome occurred in 2158 (5·3%) participants in the intensive blood pressure control group and 2811 (7·1%) participants in the standard blood pressure control group (hazard ratio 0·76, 95% credible interval [CrI] 0·72-0·81; p<0·0001). Compared with standard blood pressure control, intensive blood pressure control was associated with a 1·73% absolute risk reduction (95% CrI 1·65-1·81) in cardiovascular disease (number needed to treat 58 [95% CrI 55-61]) and a 1·82% absolute risk increase (95% CrI 1·63-2·01) for adverse events of interest (number needed to harm 55 [95% CrI 49-61]). Overall, intensive blood pressure control showed a favourable benefit-harm profile, with a net benefit of 1·14 (95% CrI 1·03-1·25), using adjudicated weighting. The net benefit remained positive when considering kidney-related adverse events (1·13 [95% CrI 1·01-1·24]).
INTERPRETATION: Compared with standard blood pressure control, intensive blood pressure control provides a net benefit between the reduction in cardiovascular events and the increase in adverse events, including renal events.
FUNDING: National Key Research and Development Program, the Ministry of Science and Technology of China; National Science and Technology Major Project; National Natural Science Foundation of China; China Academy of Chinese Medical Sciences Innovation Fund for Medical Science; and Science and Technology Program of Liaoning Province.
参考来源
- Guo X, Sun G, Xu Y, et al. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials. Lancet. 2025. PMID: 40902616. doi:10.1016/S0140-6736(25)01391-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。